Holen Sie sich die Stockscreener-App
4.13
5.06%
-0.22
Handel nachbörslich:
4.05
-0.08
-1.94%
Adc Therapeutics Sa Aktie (ADCT) Neueste Nachrichten
Is ADC Therapeutics (ADCT) Outperforming Other Medical Stocks This Year? - Yahoo Finance
ADC Therapeutics (NYSE:ADCT) Shares Down 9.2%Should You Sell? - MarketBeat
ADC Therapeutics SA: 2025 Annual Report Highlights – ZYNLONTA Pipeline, Global Partnerships, and Antibody-Drug Conjugate Innovation - Minichart
ADC Therapeutics SA (ADCT) Reports Wider Loss Q4 EPS Estimates by 85.1% - AlphaStreet
Aug Shorts: Can ADC Therapeutics SA continue delivering strong returns2026 PreEarnings & Weekly Stock Breakout Alerts - baoquankhu1.vn
ADC Therapeutics reports Q4 revenue of $22.3 million By Investing.com - Investing.com Canada
ADC Therapeutics (NYSE:ADCT) Reaches New 12-Month High Following Strong Earnings - MarketBeat
According to the latest filings submitted to the U.S. Securities and Exchange Commission (SEC), some shareholders of the biopharmaceutical company ADC Therapeutics SA may gradually sell their holdings of the company's common stock over a period of tim - Bitget
ADC Therapeutics 2025 10-K: $81.4M Revenue, $(1.12) EPS - TradingView
ADC Therapeutics SA (ADCT) Q4 2025 Earnings Call Highlights: Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada
ADC Therapeutics Q4 2025 Earnings Call Insights - Intellectia AI
ADC Therapeutics Q4 2025 Earnings Call Transcript - MarketBeat
ADC Therapeutics SA Files 8-K Report Detailing Company Information and Common Shares Listing on NYSE - Minichart
ADC Therapeutics Q4 Earnings Call Highlights - MarketBeat
ADC Therapeutics (NYSE:ADCT) Shares Gap Up After Strong Earnings - MarketBeat
ADC Therapeutics Narrows Losses, Supported By Higher Product Revenue And Ongoing Restructuring - RTTNews
ADC Therapeutics outlines $600M–$1B peak revenue target for ZYNLONTA as LOTIS-5 and LOTIS-7 advance - MSN
ADC Therapeutics reports Q4 revenue of $22.3 million - Investing.com
ADC Therapeutics (NYSE:ADCT) Posts Earnings Results, Beats Expectations By $0.23 EPS - MarketBeat
ADC Therapeutics SA (ADCT) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
ADC Therapeutics Q4 Revenue $23.06M Beats Expectations - Intellectia AI
ADC Therapeutics reports Q4 revenue $22.3M, FY2025 revenue $73.6M; cash $261.3M - TradingView
ADC THERAPEUTICS SA -REDH ($ADCT) Releases Q4 2025 Earnings - Quiver Quantitative
ADC Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Operational Update - PR Newswire
Earnings Scheduled For March 10, 2026 - Benzinga
ADC Therapeutics SA (ADCT) Posts Fourth Quarter Loss, Surpasses Revenue Projections - Bitget
Earnings Risk: Can ADC Therapeutics SA continue delivering strong returns2026 Selloffs & Scalable Portfolio Growth Ideas - baoquankhu1.vn
What to Expect from ADC Therapeutics's Earnings - Benzinga
ADC Therapeutics SA (ADCT) Q4 2025: Everything You Need to Know Ahead of Earnings - GuruFocus
Why ADC Therapeutics SA stock remains a top recommendationJuly 2025 Retail & Low Drawdown Momentum Ideas - Naître et grandir
Will ADC Therapeutics SA stock split again soonTrade Entry Report & Safe Entry Trade Reports - Naître et grandir
Valuation Update: What drives ADC Therapeutics SAs stock priceJuly 2025 WrapUp & Target Return Focused Stock Picks - baoquankhu1.vn
ADC Therapeutics SA expected to post a loss of 27 cents a shareEarnings Preview - TradingView
ADC Therapeutics (ADCT) to Release Earnings on Tuesday - MarketBeat
ADC Therapeutics to Host Q4 2025 Financial Results Call - Intellectia AI
ADC Therapeutics (NYSE:ADCT) Sees Strong Trading VolumeHere's What Happened - MarketBeat
ADC Therapeutics delivers 70% return as Fair Value target hit By Investing.com - Investing.com Nigeria
ADC Therapeutics delivers 70% return as Fair Value target hit - Investing.com
ADC Therapeutics SA (NYSE:ADCT) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
ADCT: Pivotal data and new combinations position ZYNLONTA for major growth in lymphoma markets - TradingView
ADC Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call on March 10, 2026 - StreetInsider
ADCT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan - ChartMill
ADC Therapeutics Announces Upcoming Investor Conference Schedule - Intellectia AI
ADC Therapeutics to Participate in March Investor Conferences - GuruFocus
ADC Therapeutics amends royalty deal with HealthCare Royalty - Investing.com India
ADC Therapeutics (NYSE:ADCT) Shares Up 6.7%Time to Buy? - MarketBeat
ADC Therapeutics Amends HealthCare Royalty Financing Agreement - marketscreener.com
ADC Therapeutics Announces Amended HealthCare Royalty Financing Agreement - GuruFocus
ADC Therapeutics Amends Royalty Deal, Issues New Warrants - TipRanks
ADC Therapeutics amends royalty deal with HealthCare Royalty By Investing.com - Investing.com Canada
ADC Therapeutics grants warrants to Healthcare Royalty By Investing.com - Investing.com Canada
Stepan Co recently released a project impact forecast, estimating that the cash impact over the entire project cycle will range between $29 million and $44 million, while the non-cash impact is expected to be between $58 million and $62 million. - Bitget
ADC Therapeutics SA (ADCT) recently released its performance outlook, expecting the company to enter a substantial growth phase starting in 2027. - Bitget
Healthcare Royalty Partners granted warrants to purchase approximately 9.8 million ordinary shares to ADC Therapeutics SA. - Bitget
ADC Therapeutics SA announced that, in the event of a change of control, the acquirer will continue to pay royalties to the healthcare royalty company until the originally agreed cap amount is reached. - Bitget
ADC Therapeutics announces amended Healthcare Royalty Financing agreement - marketscreener.com
ADC Therapeutics grants warrants to Healthcare Royalty - Investing.com Australia
ADC Therapeutics Amends HCR Royalty Financing, Sets $150–$200 Million Change-of-Control Payment - TradingView
ADC Therapeutics (NYSE: ADCT) amends HCR royalty deal, adds warrants - Stock Titan
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):